ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics
HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a digital twin with unprecedented biological fidelity.
Digital twins, virtual models that simulate tumor behavior, hold the promise of accelerating drug discovery and personalizing patient care. However, their predictive power is strictly limited by the quality and depth of the data on which they are trained. Current models often fail to capture the complex interplay between tumor cells and the surrounding neural tissue.
TumorTwin utilizes the unique capabilities of SPATIAL™, the company’s flagship platform designed for the analysis of 3D spatial multi-omics data. SPATIAL™ is currently the only technology on the market capable of performing morphometric spatial multi-omics analysis on brain data, putting ariadne.ai in a unique position to solve this challenge.
“We just returned from SfN in November and saw the incredible momentum spatial biology technologies have gained in neuroscience,” said Lucas Schuetz, Chief Commercial Officer at ariadne.ai. “Our SPATIAL™ platform is already being used across different disease areas by premier institutions like Stanford, Columbia University, Houston Methodist, and OHSU. It is time to make use of this established capability to tackle the complexities of Glioblastoma and provide the market with a tool that truly understands the neural-tumor interface.”
Impact on Glioblastoma Survival: With Glioblastoma patients facing a median survival of often only 12–15 months, time is critical. TumorTwin will enable researchers to identify new drug targets and simulate therapeutic outcomes in silico before clinical application. This approach aims to drastically reduce the failure rate of new cancer drugs and provide oncologists with data-driven decision support.
About ariadne.ai:
ariadne.ai is a pioneer in brain spatial biology data analysis, helping researchers decode the complexities of the brain at single-cell resolution. As a software solution provider and contract research organization (CRO), the company partners with biotech, pharma, and academic labs to turn complex imaging and spatial omics data into actionable biological insights. Its flagship platform, SPATIAL™, delivers high-precision segmentation, biomarker quantification, and multimodal data integration, enabling reproducible and scalable analysis across proteomics, transcriptomics, and morphology. ariadne.ai’s unique strength lies in neurodegeneration and neuropathology, where it provides unmatched analysis of disease hallmarks such as Aβ, Tau, α-Synuclein, and TDP-43. By linking cell phenotypes, tissue architecture, and aggregates, the company accelerates the discovery of biomarkers and therapeutic strategies in Alzheimer’s, Parkinson’s, and other brain diseases.
With ariadne.ai, imaging becomes scalable, reproducible, and insightful, powering
discoveries in brain research and beyond.
ariadne.ai (Germany) GmbH is a wholly-owned subsidiary of ariadne.ai ag, headquartered in
Buchrain, Switzerland.
